WO2011143104A1 - Methods of control and prophylaxis of inflammation and mitigation of inflammatory conditions in companion animals - Google Patents
Methods of control and prophylaxis of inflammation and mitigation of inflammatory conditions in companion animals Download PDFInfo
- Publication number
- WO2011143104A1 WO2011143104A1 PCT/US2011/035736 US2011035736W WO2011143104A1 WO 2011143104 A1 WO2011143104 A1 WO 2011143104A1 US 2011035736 W US2011035736 W US 2011035736W WO 2011143104 A1 WO2011143104 A1 WO 2011143104A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lipoic acid
- interleukin
- inflammation
- ppm
- diet
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 22
- 230000004054 inflammatory process Effects 0.000 title claims abstract description 16
- 206010061218 Inflammation Diseases 0.000 title claims abstract description 15
- 241001465754 Metazoa Species 0.000 title claims abstract description 10
- 230000004968 inflammatory condition Effects 0.000 title claims abstract description 8
- 230000000116 mitigating effect Effects 0.000 title claims abstract description 7
- 238000011321 prophylaxis Methods 0.000 title claims abstract description 7
- 235000019136 lipoic acid Nutrition 0.000 claims abstract description 33
- 229960002663 thioctic acid Drugs 0.000 claims abstract description 30
- 235000005911 diet Nutrition 0.000 claims abstract description 17
- 230000037213 diet Effects 0.000 claims abstract description 17
- 206010003246 arthritis Diseases 0.000 claims abstract description 5
- 235000013305 food Nutrition 0.000 claims description 29
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 claims description 24
- 239000000090 biomarker Substances 0.000 claims description 16
- 230000014509 gene expression Effects 0.000 claims description 10
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 claims description 8
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims description 5
- AGBQKNBQESQNJD-ZETCQYMHSA-N (S)-lipoic acid Chemical compound OC(=O)CCCC[C@H]1CCSS1 AGBQKNBQESQNJD-ZETCQYMHSA-N 0.000 claims description 5
- 235000019165 vitamin E Nutrition 0.000 claims description 5
- 239000011709 vitamin E Substances 0.000 claims description 5
- 102000008070 Interferon-gamma Human genes 0.000 claims description 4
- 108010074328 Interferon-gamma Proteins 0.000 claims description 4
- 102000003814 Interleukin-10 Human genes 0.000 claims description 4
- 108090000174 Interleukin-10 Proteins 0.000 claims description 4
- 102000004388 Interleukin-4 Human genes 0.000 claims description 4
- 108090000978 Interleukin-4 Proteins 0.000 claims description 4
- 102000004889 Interleukin-6 Human genes 0.000 claims description 4
- 108090001005 Interleukin-6 Proteins 0.000 claims description 4
- 229930003427 Vitamin E Natural products 0.000 claims description 4
- 229960004203 carnitine Drugs 0.000 claims description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 4
- 229960003130 interferon gamma Drugs 0.000 claims description 4
- 229940046009 vitamin E Drugs 0.000 claims description 4
- 201000008482 osteoarthritis Diseases 0.000 claims description 3
- 102000019034 Chemokines Human genes 0.000 claims description 2
- 108010012236 Chemokines Proteins 0.000 claims description 2
- 101000668058 Infectious salmon anemia virus (isolate Atlantic salmon/Norway/810/9/99) RNA-directed RNA polymerase catalytic subunit Proteins 0.000 claims description 2
- 102000003812 Interleukin-15 Human genes 0.000 claims description 2
- 108090000172 Interleukin-15 Proteins 0.000 claims description 2
- 108090000171 Interleukin-18 Proteins 0.000 claims description 2
- 102000003810 Interleukin-18 Human genes 0.000 claims description 2
- 102000000588 Interleukin-2 Human genes 0.000 claims description 2
- 108010002350 Interleukin-2 Proteins 0.000 claims description 2
- 102000000704 Interleukin-7 Human genes 0.000 claims description 2
- 108010002586 Interleukin-7 Proteins 0.000 claims description 2
- 102000004890 Interleukin-8 Human genes 0.000 claims description 2
- 108090001007 Interleukin-8 Proteins 0.000 claims description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 2
- 230000003399 chemotactic effect Effects 0.000 claims description 2
- 229940076144 interleukin-10 Drugs 0.000 claims description 2
- 229940028885 interleukin-4 Drugs 0.000 claims description 2
- 229940100601 interleukin-6 Drugs 0.000 claims description 2
- 229940100994 interleukin-7 Drugs 0.000 claims description 2
- 229940096397 interleukin-8 Drugs 0.000 claims description 2
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 claims description 2
- 210000001616 monocyte Anatomy 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 230000004936 stimulating effect Effects 0.000 claims description 2
- 125000004185 ester group Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 241000282472 Canis lupus familiaris Species 0.000 abstract description 28
- 241000282326 Felis catus Species 0.000 abstract description 5
- 208000006820 Arthralgia Diseases 0.000 abstract description 4
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 17
- 108090000623 proteins and genes Proteins 0.000 description 13
- 230000002757 inflammatory effect Effects 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 6
- 239000005556 hormone Substances 0.000 description 5
- 229940088597 hormone Drugs 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 239000002858 neurotransmitter agent Substances 0.000 description 4
- 241000282465 Canis Species 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- -1 500-2000 IU/kg Chemical compound 0.000 description 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 2
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 2
- 230000007351 Aβ plaque formation Effects 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 102000005915 GABA Receptors Human genes 0.000 description 2
- 108010005551 GABA Receptors Proteins 0.000 description 2
- 102100021852 Neuronal cell adhesion molecule Human genes 0.000 description 2
- 101710130688 Neuronal cell adhesion molecule Proteins 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 230000036995 brain health Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 230000019771 cognition Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 238000007427 paired t-test Methods 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 241000588807 Bordetella Species 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102100024646 Cell adhesion molecule 2 Human genes 0.000 description 1
- 101710197434 Cell adhesion molecule 2 Proteins 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- 208000000655 Distemper Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102000018899 Glutamate Receptors Human genes 0.000 description 1
- 108010027915 Glutamate Receptors Proteins 0.000 description 1
- 102100022197 Glutamate receptor ionotropic, kainate 1 Human genes 0.000 description 1
- 101710112359 Glutamate receptor ionotropic, kainate 1 Proteins 0.000 description 1
- 102100022758 Glutamate receptor ionotropic, kainate 2 Human genes 0.000 description 1
- 101710112360 Glutamate receptor ionotropic, kainate 2 Proteins 0.000 description 1
- 101000577555 Homo sapiens Neuritin Proteins 0.000 description 1
- 101000740126 Homo sapiens Orphan sodium- and chloride-dependent neurotransmitter transporter NTT5 Proteins 0.000 description 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 1
- 102100028749 Neuritin Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 102000005031 SLC6A15 Human genes 0.000 description 1
- 108060007754 SLC6A15 Proteins 0.000 description 1
- 102000005034 SLC6A16 Human genes 0.000 description 1
- 108060007755 SLC6A16 Proteins 0.000 description 1
- 102000005026 SLC6A18 Human genes 0.000 description 1
- 108060007757 SLC6A18 Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102000034337 acetylcholine receptors Human genes 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000036626 alertness Effects 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 208000014058 canine distemper Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000007370 cognitive improvement Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 150000002148 esters Chemical group 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 239000006014 omega-3 oil Substances 0.000 description 1
- 150000002898 organic sulfur compounds Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000003979 response to food Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 159000000000 sodium salts Chemical group 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/116—Heterocyclic compounds
- A23K20/121—Heterocyclic compounds containing oxygen or sulfur as hetero atom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
- A23K20/147—Polymeric derivatives, e.g. peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/174—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the invention relates to methods of control and prophylaxis of inflammation and mitigation of inflammatory conditions, particularly arthritis and joint pain, in
- companion animals e.g., dogs or cats, comprising administering a diet comprising lipoic acid.
- LA Lipoic acid
- RLA Lipoic acid
- SLA S-(-)-lipoic acid
- R/S-LA Racemic mixture
- Both RLA and R/S-LA are available as over-the-counter nutritional supplements and have been used nutritionally and clinically since the 1950s for a number of diseases and conditions.
- LA has been used in animal food, for example Hill's Prescription Diet canine b/ d® , which is believed to enhance alertness and cognition particularly in older dogs.
- Osteoarthritis is a chronic, degenerative joint disease that is caused by the progressive inflammation and deterioration of the cartilage, bone, and soft tissue of one or more joints.
- Rheumatoid arthritis is an autoimmune condition that causes
- the invention provides methods of control and prophylaxis of inflammation and mitigation of inflammatory conditions, particularly arthritis and joint pain, in companion animals, e.g., dogs or cats, comprising administering a diet comprising lipoic acid, e.g., for a period of at least two weeks, e.g., wherein the diet comprises a food having 10-10,000 ppm of lipoic acid, e.g., a dry food comprising 50-200 ppm lipoic acid.
- the invention provides methods of control and prophylaxis of inflammation and mitigation of inflammatory conditions, particularly arthritis and joint pain, in companion animals, e.g., dogs or cats, comprising measuring expression of biomarkers for inflammation, and administering a diet containing lipoic acid, e.g., for a period of at least two weeks, e.g., wherein the diet comprises a food having 10-10,000 ppm of lipoic acid, e.g., a dry food comprising 50-200 ppm lipoic acid, to reduce expression of one or more of the biomarkers for inflammation.
- the diet for use in the methods herein includes for example, a canine diet comprising at least 500 IU/kg Vitamin E, e.g., 500-2000 IU/kg, at least about 40 ppm vitamin C, e.g., 40-200 ppm, at least 50 ppm carnitine, e.g., 50-300 ppm and at least 50 ppm lipoic acid, for example 50-250 ppm, for example a canine diet comprising:
- Vitamin E IU/kg 500-2000
- Vitamin C ppm 40-200
- the lipoic acid is, for example, R-(+)-lipoic acid (RLA) and S-(-)-lipoic acid (SLA) or a racemic mixture R/S-lipoic acid (R/S-LA), preferably RLA or R/S-LA, in free or nutritionally acceptable salt or ester form, preferably in free form or sodium salt form.
- RLA R-(+)-lipoic acid
- SLA S-(-)-lipoic acid
- R/S-LA racemic mixture R/S-lipoic acid
- R/S-LA preferably RLA or R/S-LA
- the biomarkers for inflammation include, for example, any one or more of the following: Tumor necrosis factor alpha, GM-colony stimulating factor, Monocyte chemotatic protein-1, Interferon gamma, Interleukin-10, Interleukin-15, Interleukin-18, Interleukin-2, Interleukin-4, Interleukin-6, Interleukin-7, Interleukin-8, Interferon gamma induced protein-10, KC chemokine.
- Example 1 Effect of lipoic acid diet on inflammatory biomarkers in geriatric dogs
- geriatric beagle dogs Twenty-nine geriatric beagle dogs (initial weight, 13.51 ⁇ 1.66 kg, age, 10.7 ⁇ 2.33 years) were included in the study. All dogs were fed a control maintenance food for 28 days followed by the test food. The test food contains increased levels of omega 3 fatty acids, lipoic acid, antioxidants from a fruit and vegetable blend, Vitamins C and E, and L- carnitine. Serum and whole blood samples were collected on the last day of the control food (day 0) and after 14 days on the test food. Inflammatory and hormone biomarkers as well as gene expression changes were measured.
- geriatric dogs fed the test food had lower IL-4, IL-6, IL-10, KC, and total cytokines. No differences in hormone biomarkers were detected. Geriatric dogs fed the test food also had 1123 genes that were up or down regulated compared to day 0. Of these, genes associated with amyloid beta plaque formation were down-regulated while genes associated with clearance of beta amyloid plaque were up-regulated. In addition, genes associated with neurotransmitter signaling and cell adhesion were significantly up-regulated when geriatric dogs were fed the test food compared to the day 0 on the control. This study provides gene expression evidence that support the benefits observed in geriatric dogs for memory and behavior associated responses previously shown with the test food.
- test food has been shown to improve memory and cognition in geriatric dogs to a level similar to young dogs as measured by task and discrimination testing.
- Inflammation plays a major role in development of many disease processes including general aging.
- biochemical measures related to cognitive improvement such as gene expression have only seen limited use in the dog.
- Dogs Twenty-nine neutered/ spayed beagle dogs were identified for this study and fed the test food for 28 days. Dogs were considered healthy by physical exam and serum chemistry. The study protocol was reviewed and approved by the Institutional Animal Care and Use Committee. All dogs were immunized against canine distemper, adenovirus, parvovirus, bordetella, and rabies, and none had chronic systemic disease on the basis of results of physical examination, complete blood count determination, serum biochemical analyses, urinalysis, and fecal examination for parasites. Dogs experienced behavioral enrichment through interactions with each other, by daily interaction and play time with caretakers, daily opportunities to run and exercise outside and access to toys.
- Plasma biomarkers - A paired t-test analysis was used to determine changes in inflammatory and hormone biomarkers using SAS version 9.0 in response to food. Total cytokines were calculated using all cytokines.
- Up-regulated genes are shown as positive fold-changes.
- Down-regulated genes are shown as negative fold-changes.
- Vitamin E IU/kg 94 1183
- Acetylcholine receptor alpha 6 1.3
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Birds (AREA)
- Rheumatology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Fodder In General (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Feed For Specific Animals (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention relates to methods of control and prophylaxis of inflammation and mitigation of inflammatory conditions, particularly arthritis and joint pain, in companion animals, e.g., dogs or cats, comprising administering a diet comprising lipoic acid.
Description
METHODS OF CONTROL AND PROPHYLAXIS OF INFLAMMATION AND MITIGATION OF INFLAMMATORY CONDITIONS IN COMPANION ANIMALS
Field of the Invention
[0001] The invention relates to methods of control and prophylaxis of inflammation and mitigation of inflammatory conditions, particularly arthritis and joint pain, in
companion animals, e.g., dogs or cats, comprising administering a diet comprising lipoic acid.
Background of the Invention
[0002] Lipoic acid (LA) is an organosulfur compound derived from octanoic acid. LA contains two vicinal sulfur atoms (at C6 and C8) attached via a disulfide bond and is thus considered to be oxidized (although either sulfur atom can exist in higher oxidation states). The carbon atom at C6 is chiral and the molecule exists as two enantiomers R-(+)-lipoic acid (RLA) and S-(-)-lipoic acid (SLA) and as a racemic mixture R/S-lipoic acid (R/S-LA). Only the R-(+)-enantiomer exists in nature and is an essential cofactor of four mitochondrial enzyme complexes. Both RLA and R/S-LA are available as over-the-counter nutritional supplements and have been used nutritionally and clinically since the 1950s for a number of diseases and conditions. LA has been used in animal food, for example Hill's Prescription Diet canine b/ d® , which is believed to enhance alertness and cognition particularly in older dogs.
[0003] Osteoarthritis is a chronic, degenerative joint disease that is caused by the progressive inflammation and deterioration of the cartilage, bone, and soft tissue of one or more joints. Rheumatoid arthritis is an autoimmune condition that causes
inflammation and damage to the joints. Both are chronic inflammatory conditions and are common in older dogs and cats. Because the damage to the joints is progressive and largely irreversible, it is desirable to identify and address the inflammatory process proactively.
Summary of the Invention
[0004] The invention provides methods of control and prophylaxis of inflammation and mitigation of inflammatory conditions, particularly arthritis and joint pain, in companion animals, e.g., dogs or cats, comprising administering a diet comprising lipoic acid, e.g., for a period of at least two weeks, e.g., wherein the diet comprises a food having 10-10,000 ppm of lipoic acid, e.g., a dry food comprising 50-200 ppm lipoic acid.
[0005] In a further embodiment, the invention provides methods of control and prophylaxis of inflammation and mitigation of inflammatory conditions, particularly arthritis and joint pain, in companion animals, e.g., dogs or cats, comprising measuring expression of biomarkers for inflammation, and administering a diet containing lipoic acid, e.g., for a period of at least two weeks, e.g., wherein the diet comprises a food having 10-10,000 ppm of lipoic acid, e.g., a dry food comprising 50-200 ppm lipoic acid, to reduce expression of one or more of the biomarkers for inflammation.
Detailed Description of the Invention
[0006] The diet for use in the methods herein includes for example, a canine diet comprising at least 500 IU/kg Vitamin E, e.g., 500-2000 IU/kg, at least about 40 ppm vitamin C, e.g., 40-200 ppm, at least 50 ppm carnitine, e.g., 50-300 ppm and at least 50 ppm lipoic acid, for example 50-250 ppm, for example a canine diet comprising:
Calcium, % 0.1-1
Phosphorus, % 0.1-1
Vitamin E, IU/kg 500-2000
Vitamin C, ppm 40-200
Carnitine, ppm 50-300
Lipoic acid, ppm 50-250
Vegetable blend, % 1-10
[0007] The lipoic acid is, for example, R-(+)-lipoic acid (RLA) and S-(-)-lipoic acid (SLA) or a racemic mixture R/S-lipoic acid (R/S-LA), preferably RLA or R/S-LA, in free or nutritionally acceptable salt or ester form, preferably in free form or sodium salt form.
[0008] The biomarkers for inflammation include, for example, any one or more of the following: Tumor necrosis factor alpha, GM-colony stimulating factor, Monocyte chemotatic protein-1, Interferon gamma, Interleukin-10, Interleukin-15, Interleukin-18, Interleukin-2, Interleukin-4, Interleukin-6, Interleukin-7, Interleukin-8, Interferon gamma induced protein-10, KC chemokine.
Example 1 - Effect of lipoic acid diet on inflammatory biomarkers in geriatric dogs
[0009] A study was conducted to evaluate the effect of a food composition on
inflammatory biomarkers and gene expression in healthy geriatric dogs. Twenty-nine geriatric beagle dogs (initial weight, 13.51 ± 1.66 kg, age, 10.7 ± 2.33 years) were included in the study. All dogs were fed a control maintenance food for 28 days followed by the test food. The test food contains increased levels of omega 3 fatty acids, lipoic acid, antioxidants from a fruit and vegetable blend, Vitamins C and E, and L- carnitine. Serum and whole blood samples were collected on the last day of the control food (day 0) and after 14 days on the test food. Inflammatory and hormone biomarkers
as well as gene expression changes were measured. RNA was extracted according to the procedures provided in the PAXgene Blood RNA Kit Handbook (Qiagen, Valencia, CA). RNA was hybridized to an Affymetrix GeneChip Canine-2 Genome Arrays and normalized using Robust Multi-Array Average. Transcripts having a P < 0.05
(following a false discovery rate adjustment value of 0.1) and a fold change range of at least 1.3 were considered different. After consuming the test food, geriatric dogs fed the test food had lower IL-4, IL-6, IL-10, KC, and total cytokines. No differences in hormone biomarkers were detected. Geriatric dogs fed the test food also had 1123 genes that were up or down regulated compared to day 0. Of these, genes associated with amyloid beta plaque formation were down-regulated while genes associated with clearance of beta amyloid plaque were up-regulated. In addition, genes associated with neurotransmitter signaling and cell adhesion were significantly up-regulated when geriatric dogs were fed the test food compared to the day 0 on the control. This study provides gene expression evidence that support the benefits observed in geriatric dogs for memory and behavior associated responses previously shown with the test food.
[0010] The test food has been shown to improve memory and cognition in geriatric dogs to a level similar to young dogs as measured by task and discrimination testing.
However, the underlying mechanism by which these improvements are observed has not been defined. Inflammation plays a major role in development of many disease processes including general aging. In addition, biochemical measures related to cognitive improvement such as gene expression have only seen limited use in the dog.
[0011] The objective of this study was to determine the effect of the test food on inflammatory and hormone biomarkers as well as gene expression changes in geriatric dogs.
[0012] Twenty-nine neutered/ spayed beagle dogs were identified for this study and fed the test food for 28 days. Dogs were considered healthy by physical exam and serum chemistry. The study protocol was reviewed and approved by the Institutional Animal Care and Use Committee. All dogs were immunized against canine distemper, adenovirus, parvovirus, bordetella, and rabies, and none had chronic systemic disease
on the basis of results of physical examination, complete blood count determination, serum biochemical analyses, urinalysis, and fecal examination for parasites. Dogs experienced behavioral enrichment through interactions with each other, by daily interaction and play time with caretakers, daily opportunities to run and exercise outside and access to toys. Prior to sample collection at day 0, all dogs were fed a basal maintenance control food for 28 days. Dogs were then switched to the test food and samples collected after 14 days. Blood was drawn and collected into PAXgene tubes and stored at -80°C until evaluation. Canine-2 Affymetrix Genechip microarrays were used to identify gene differences at day 14 compared to day 0.
[0013] Plasma biomarkers - A paired t-test analysis was used to determine changes in inflammatory and hormone biomarkers using SAS version 9.0 in response to food. Total cytokines were calculated using all cytokines.
[0014] Genes - Gene expression was normalized using Robust Multi-Array average and Partek analysis tool was used to determine differences. Genes having a P < 0.05
(following a false discovery rate adjustment of Q = 0.1) and a fold-change of at least 1.25 were considered different among the two groups. Up-regulated genes are shown as positive fold-changes. Down-regulated genes are shown as negative fold-changes.
Table 1: Contents of the Diets
Phosphorus, % 0.60 0.58
Vitamin E, IU/kg 94 1183
Carnitine, ppm 10 291
Lipoic acid, ppm 0 101
Vegetable blend, % 0 6.30
Table 2: Inflammatory and hormone biomarkers measured in plasma in response to test food (SE=Standard error of the mean):
Plasma Day O Day 14 Paired t-test day 0 vs
Biomarker Mean Mean SE* dayl4
Table 3: Genes associated with brain health and function:
Neuronal cell adhesion molecule 1.4
Neruonal cell adhesion molecule 2 1.5
Neuronal cell adhesion molecule short isoform 1.4
Related to neurotransmitter signaling and transporters
GABA receptor A 1.3
GABA receptor B 1.3
Glutamate receptor 5 1.3
Glutamate receptor 6 1.3
Glutamate receptor 8 1.3
NMDA 2B 1.4
Neuritin 1 1.3
Acetylcholine receptor alpha 6 1.3
SLC6A15 1.3
SLC6A16 1.3
SLC6A18 1.3
Cadherin 2 1.3
Sodium- and chloride-dependent neurotransmitter
transporter NTT5 1.3
[0015] Clinical studies have shown that feeding the test food to geriatric dogs can help restore youthful energy and improve memory/ task ability to a similar level of young adult dogs. In the current study, switching healthy geriatric dogs to the test food after feeding a maintenance control food, demonstrated a decrease in inflammatory markers IL-4, IL-10, IL-6, KC, and total cytokines. Additionally, genes associated with amyloid beta plaque formation were decreased while other genes related to beta-amyloid removal or neurotransmitter signaling were increased.
[0016] This study suggests that feeding the test food has a positive effect on quality of life in geriatric dogs through decreasing inflammatory biomarkers and potentially through altering expression of brain health related genes.
Claims
1. A method of control or prophylaxis of inflammation and/ or mitigation of
inflammatory conditions in a companion animal comprising administering a diet comprising lipoic acid.
2. The method of claim 1 wherein the diet is administered for a period of at least two weeks.
3. The method of claim 1 or 2 wherein the diet comprises a food having 10-10,000 ppm of lipoic acid
4. The method of claim 1 or any of the preceding claims, wherein the diet comprises a dry food comprising 50-200 ppm lipoic acid.
5. The method of claim 1 or any of the preceding claims, wherein the condition to be controlled, prevented or mitigated is arthritis.
6. The method of claim 1 or any of the preceding claims, wherein the condition to be treated is controlled, prevented or mitigated is osteoarthritis.
7. The method of claim 1 or any of the preceding claims, wherein the companion
animal is a dog or a cat.
8. The method of claim 1 or any of the preceding claims, wherein the diet comprises at least 500 IU/kg Vitamin E, at least 200 ppm carnitine, and at least 50 ppm lipoic acid.
9. The method of claim 1 or any of the preceding claims wherein the lipoic acid is R- (+)-lipoic acid (RLA) or a racemic mixture R/S-lipoic acid (R/S-LA), in free or nutritionally acceptable salt or ester form.
10. The method of claim 1 or any of the preceding claims, further comprising measuring expression of biomarkers for inflammation.
11. The method of claim 10 wherein biomarkers for inflammation comprise one or more biomarkers selected from tumor necrosis factor alpha, GM-colony stimulating factor, Monocyte chemotatic protein-1, Interferon gamma, Interleukin-10, Interleukin-15, Interleukin-18, Inter leukin-2, Interleukin-4, Interleukin-6, Interleukin-7, Inter leukin- 8, Interferon gamma induced protein-10, and KC chemokine.
12. The use of lipoic acid in the manufacture of a pet food for use in any of the methods of the foregoing claims.
13. Lipoic acid for use in any of the methods of the foregoing claims.
Priority Applications (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11720683A EP2568824A1 (en) | 2010-05-12 | 2011-05-09 | Methods of control and prophylaxis of inflammation and mitigation of inflammatory conditions in companion animals |
| RU2012153558/13A RU2525579C2 (en) | 2010-05-12 | 2011-05-09 | Methods of control and prevention of inflammation and relief of inflammatory conditions in companion animals |
| US13/642,561 US20130041020A1 (en) | 2010-05-12 | 2011-05-09 | Methods of Control and Prophylaxis of Inflammation and Mitigation of Inflammatory Conditions in Companion Animals |
| CA2799168A CA2799168C (en) | 2010-05-12 | 2011-05-09 | Methods of control and prophylaxis of inflammation and mitigation of inflammatory conditions in companion animals |
| CN201180023575XA CN102933092A (en) | 2010-05-12 | 2011-05-09 | Methods of control and prophylaxis of inflammation and mitigation of inflammatory conditions in companion animals |
| AU2011253202A AU2011253202B2 (en) | 2010-05-12 | 2011-05-09 | Methods of control and prophylaxis of inflammation and mitigation of inflammatory conditions in companion animals |
| BR112012025772A BR112012025772A2 (en) | 2010-05-12 | 2011-05-09 | methods of control and prophylaxis of inflammation and mitigation of inflammatory conditions in pets |
| JP2013510203A JP2013532128A (en) | 2010-05-12 | 2011-05-09 | Methods for suppressing and preventing inflammation in pet animals and alleviating inflammatory conditions |
| ZA2012/08036A ZA201208036B (en) | 2010-05-12 | 2012-10-24 | Methods of control and prophylaxis of inflammation and mitagation of inflammatory conditions in companion animals |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33403710P | 2010-05-12 | 2010-05-12 | |
| US61/334,037 | 2010-05-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2011143104A1 true WO2011143104A1 (en) | 2011-11-17 |
Family
ID=44146887
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2011/035736 WO2011143104A1 (en) | 2010-05-12 | 2011-05-09 | Methods of control and prophylaxis of inflammation and mitigation of inflammatory conditions in companion animals |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20130041020A1 (en) |
| EP (1) | EP2568824A1 (en) |
| JP (2) | JP2013532128A (en) |
| CN (2) | CN102933092A (en) |
| AU (1) | AU2011253202B2 (en) |
| BR (1) | BR112012025772A2 (en) |
| CA (1) | CA2799168C (en) |
| RU (1) | RU2525579C2 (en) |
| WO (1) | WO2011143104A1 (en) |
| ZA (1) | ZA201208036B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2707717A1 (en) * | 2011-05-10 | 2014-03-19 | Nestec S.A. | Methods for diagnosing degenerative joint disease |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017104277A1 (en) * | 2015-12-17 | 2017-06-22 | 昭和電工株式会社 | Antiinflammatory agent and antiinflammatory composition |
| WO2018109670A1 (en) * | 2016-12-15 | 2018-06-21 | Nestec Sa | Compositions and methods that modulate vitamin d and bone mineral content in a companion animal |
| CA3114312A1 (en) | 2018-11-02 | 2020-05-07 | Hill's Pet Nutrition, Inc. | Pet food compositions |
| CA3164206A1 (en) * | 2019-12-16 | 2021-06-24 | Hill's Pet Nutrition, Inc. | Pet food compositions |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5569670A (en) | 1992-06-05 | 1996-10-29 | Asta Medica Aktiengesellschaft | Combination medications containing alpha-lipoic acid and related |
| EP1118332A1 (en) | 2000-01-20 | 2001-07-25 | Innovet Italia S.r.l. | A composition for treating degenerative joint diseases |
| WO2004112776A2 (en) | 2003-06-23 | 2004-12-29 | Advanced Bionutrition (Europe) Limited | Inflammatory disease treatment |
| US20080069834A1 (en) | 2004-11-09 | 2008-03-20 | Zicker Steven C | Use of Antioxidants for Gene Modulation |
| US20090182032A1 (en) | 2000-10-31 | 2009-07-16 | Hill's Pet Nutrition, Inc. | Companion animal compositions including lipoic acid and methods of use thereof |
| WO2010009468A1 (en) | 2008-07-18 | 2010-01-21 | Hill's Pet Nutrition, Inc. | Method for enhancing the quality of life of a senior animal |
| WO2010078322A1 (en) * | 2008-12-30 | 2010-07-08 | Hill's Pet Nutrition, Inc. | Use of lipoic acid for treating or preventing degenerative joint conditions, osteoarthritis, cartilage damage, and related disorders in companion animals |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020076470A1 (en) * | 2000-10-31 | 2002-06-20 | Colgate-Palmolive Company | Composition and method |
| US6923960B2 (en) * | 2001-10-03 | 2005-08-02 | Vsl Pharmaceuticals Inc. | Antioxidant combination composition and use thereof |
| US8637495B2 (en) * | 2004-07-01 | 2014-01-28 | Nestec S.A. | Osteoarthritis diet formulations |
| WO2006058248A2 (en) * | 2004-11-24 | 2006-06-01 | Hill's Pet Nutrition, Inc. | Methods for increasing the immune response in an animal |
| AU2005322887B2 (en) * | 2004-12-30 | 2010-03-11 | Hill's Pet Nutrition, Inc. | Methods for enhancing the quality of life of a senior animal |
| EP2323638B1 (en) * | 2008-07-18 | 2014-05-07 | Hill's Pet Nutrition, Inc. | Compositions and methods for treating osteoarthritis |
-
2011
- 2011-05-09 AU AU2011253202A patent/AU2011253202B2/en active Active
- 2011-05-09 WO PCT/US2011/035736 patent/WO2011143104A1/en active Application Filing
- 2011-05-09 CN CN201180023575XA patent/CN102933092A/en active Pending
- 2011-05-09 CN CN201410479815.2A patent/CN104286456A/en active Pending
- 2011-05-09 BR BR112012025772A patent/BR112012025772A2/en not_active Application Discontinuation
- 2011-05-09 EP EP11720683A patent/EP2568824A1/en not_active Ceased
- 2011-05-09 CA CA2799168A patent/CA2799168C/en active Active
- 2011-05-09 US US13/642,561 patent/US20130041020A1/en not_active Abandoned
- 2011-05-09 JP JP2013510203A patent/JP2013532128A/en active Pending
- 2011-05-09 RU RU2012153558/13A patent/RU2525579C2/en not_active IP Right Cessation
-
2012
- 2012-10-24 ZA ZA2012/08036A patent/ZA201208036B/en unknown
-
2014
- 2014-12-05 JP JP2014246783A patent/JP6334379B2/en active Active
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5569670A (en) | 1992-06-05 | 1996-10-29 | Asta Medica Aktiengesellschaft | Combination medications containing alpha-lipoic acid and related |
| EP1118332A1 (en) | 2000-01-20 | 2001-07-25 | Innovet Italia S.r.l. | A composition for treating degenerative joint diseases |
| US20090182032A1 (en) | 2000-10-31 | 2009-07-16 | Hill's Pet Nutrition, Inc. | Companion animal compositions including lipoic acid and methods of use thereof |
| WO2004112776A2 (en) | 2003-06-23 | 2004-12-29 | Advanced Bionutrition (Europe) Limited | Inflammatory disease treatment |
| EP1635810A2 (en) * | 2003-06-23 | 2006-03-22 | Advanced Bionutrition (Europe) Limited | Inflammatory disease treatment |
| US20080069834A1 (en) | 2004-11-09 | 2008-03-20 | Zicker Steven C | Use of Antioxidants for Gene Modulation |
| WO2010009468A1 (en) | 2008-07-18 | 2010-01-21 | Hill's Pet Nutrition, Inc. | Method for enhancing the quality of life of a senior animal |
| WO2010078322A1 (en) * | 2008-12-30 | 2010-07-08 | Hill's Pet Nutrition, Inc. | Use of lipoic acid for treating or preventing degenerative joint conditions, osteoarthritis, cartilage damage, and related disorders in companion animals |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2707717A1 (en) * | 2011-05-10 | 2014-03-19 | Nestec S.A. | Methods for diagnosing degenerative joint disease |
| EP2707717A4 (en) * | 2011-05-10 | 2014-12-24 | Nestec Sa | Methods for diagnosing degenerative joint disease |
| US9322832B2 (en) | 2011-05-10 | 2016-04-26 | Nestec S.A. | Methods for diagnosing degenerative joint disease |
Also Published As
| Publication number | Publication date |
|---|---|
| JP6334379B2 (en) | 2018-05-30 |
| CA2799168C (en) | 2015-07-07 |
| CA2799168A1 (en) | 2011-11-17 |
| AU2011253202B2 (en) | 2014-04-24 |
| RU2525579C2 (en) | 2014-08-20 |
| ZA201208036B (en) | 2017-08-30 |
| JP2015071633A (en) | 2015-04-16 |
| JP2013532128A (en) | 2013-08-15 |
| US20130041020A1 (en) | 2013-02-14 |
| BR112012025772A2 (en) | 2015-09-22 |
| RU2012153558A (en) | 2014-06-20 |
| CN104286456A (en) | 2015-01-21 |
| EP2568824A1 (en) | 2013-03-20 |
| CN102933092A (en) | 2013-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2799168C (en) | Methods of control and prophylaxis of inflammation and mitigation of inflammatory conditions in companion animals | |
| AU2011253202A1 (en) | Methods of control and prophylaxis of inflammation and mitigation of inflammatory conditions in companion animals | |
| AU2016281870B2 (en) | Compositions and methods for enhancing neurogenesis in animals | |
| Aleman et al. | Evaluation of epidemiological, clinical, and pathological features of neuroaxonal dystrophy in Quarter Horses | |
| Koo et al. | Diet complexity and l-threonine supplementation: effects on growth performance, immune response, intestinal barrier function, and microbial metabolites in nursery pigs | |
| WO2010009474A1 (en) | Compositions and methods for treating osteoarthritis | |
| EP2315532A2 (en) | Compositions and methods for treating disorders associated with overweight animals | |
| RU2411746C2 (en) | Composition (versions) and method (versions) of prevention or treatment of chronic renal insuffuciency in felidae with hyperthyroidism | |
| Ranard et al. | Synthetic α-tocopherol, compared with natural α-tocopherol, downregulates myelin genes in cerebella of adolescent Ttpa-null mice | |
| Wrigglesworth et al. | High-throughput glycomic analyses reveal unique oligosaccharide profiles of canine and feline milk samples | |
| Pusterla et al. | [alpha]-tocopherol concentrations in equine serum and cerebrospinal fluid after vitamin E supplementation | |
| Jelinek et al. | Biochemical and Hematological Values in the Blood of Rams during Rearing | |
| JP5698427B2 (en) | Antidiarrheal composition containing glutamine | |
| Adhikari et al. | Effects of total sulfur amino acids on growth performance, immunity, and meat yield in broilers fed diets with and without antibiotics | |
| US20120258194A1 (en) | Phaseolus vulgaris as a functional food ingredient for obesity and associated metabolic disorders | |
| Bermingham et al. | Nutritional needs and health outcomes of ageing cats and dogs: is it time for updated nutrient guidelines? | |
| Xie et al. | Dietary ethylenediamine dihydroiodide improves intestinal health in Cherry Valley ducks | |
| Dong et al. | Effect of organic zinc on production performances, meat performances, apparent nutrients digestibility and gut microbiota of broilers in low protein diets | |
| EP2568823B1 (en) | Methods of diagnosis, control and prophylaxis of inflammation and mitigation of inflammatory conditions in felines | |
| DAINA et al. | NUTRIENT CONTENT AND CALORIC DENSITY ASSESSMENT OF DIFFERENT TYPES OF SENIOR COMMERCIAL CAT FOOD | |
| Žymantienė et al. | Assessment of gut microbiota and serum biochemistry parameters in rats fed commercial pellet diet containing different protein content. | |
| Valle et al. | Effect of the association of diet, omega-three, and antioxidants in dogs with chronic kidney disease. | |
| Martínez-Aranzales et al. | Fecal Microbiome of Horses with and Without Crib-Biting Behavior: A Comparative Study | |
| CN118338897A (en) | Compositions and methods for providing health benefits in animals using amino acid blends | |
| AU2011253200A1 (en) | Methods of diagnosis, control and prophylaxis of inflammation and mitigation of inflammatory conditions in felines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WWE | Wipo information: entry into national phase |
Ref document number: 201180023575.X Country of ref document: CN |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11720683 Country of ref document: EP Kind code of ref document: A1 |
|
| DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 13642561 Country of ref document: US |
|
| ENP | Entry into the national phase |
Ref document number: 2799168 Country of ref document: CA |
|
| ENP | Entry into the national phase |
Ref document number: 2013510203 Country of ref document: JP Kind code of ref document: A |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| ENP | Entry into the national phase |
Ref document number: 2011253202 Country of ref document: AU Date of ref document: 20110509 Kind code of ref document: A |
|
| ENP | Entry into the national phase |
Ref document number: 2012153558 Country of ref document: RU Kind code of ref document: A |
|
| REEP | Request for entry into the european phase |
Ref document number: 2011720683 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2011720683 Country of ref document: EP |
|
| REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112012025772 Country of ref document: BR |
|
| ENP | Entry into the national phase |
Ref document number: 112012025772 Country of ref document: BR Kind code of ref document: A2 Effective date: 20121009 |